Anlotinib Hydrochloride

Catequentinib Hydrochloride is the hydrochloride salt form of catequentinib, a receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic and anti-angiogenic activities. Upon administration, catequentinib targets multiple RTKs, including vascular endothelial growth factor receptor type 2 (VEGFR2) and type 3 (VEGFR3). This agent may both inhibit angiogenesis and halt tumor cell growth. It is grouped under the following drug class(es): Tyrosine Kinase Inhibitors and VEGF inhibitors. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Anlotinib dihydrochloride and Catequentinib Hydrochloride. Its PubChem CID is 57380530.